A migraine drugmaker heads to the public markets through reverse merger

Mentari Therapeutics to Go Public via Reverse Merger

Mentari Therapeutics, a spinout from Paragon Therapeutics, is set to go public through a reverse merger with InMed Pharmaceuticals. The deal, announced on Tuesday, is expected to close in the latter half of this year, creating a combined company with a pro forma equity value of approximately $421 million. This includes a concurrent private placement raising about $290 million. The new entity, operating under the Mentari name, will focus on developing antibody drugs for migraine prevention, specifically targeting PACAP and CGRP proteins. The funding is anticipated to support operations through 2028, by which time Mentari expects to have clinical data for its two lead programs, MT-001 and MT-002.

• Mentari Therapeutics is entering the public market via a reverse merger with InMed Pharmaceuticals, a transaction already approved by both boards and slated for completion in the latter half of the current year. The combined entity is projected to have a pro forma equity value of approximately $421 million, bolstered by a concurrent private placement that secured gross proceeds of about $290 million. InMed shareholders are expected to own roughly 1.5% of the new company.
• The newly formed Mentari will concentrate on advancing its lead programs, MT-001 and MT-002, which are antibody drugs designed to prevent migraines by inhibiting PACAP and, for MT-002, also CGRP. MT-001 is on track to deliver Phase 2 proof-of-concept data in 2028, while Phase 1 data for the bispecific antibody MT-002, from a study in healthy volunteers, is anticipated in 2027.
• Mentari's strategy targets the unmet needs of migraine patients, as current treatments often fall short, with nearly half of patients not achieving a 50% reduction in monthly migraine days and fewer than one-third reporting a 75% reduction. By focusing on PACAP and CGRP inhibition, Mentari aims to offer novel therapeutic options with the potential to significantly expand and reshape the existing migraine treatment and prevention market.

Why Current Migraine Treatments Fall Short for Many

Despite advances in migraine therapeutics, significant gaps remain in care delivery and access across diverse patient populations. Recent research has identified critical areas where current treatment paradigms fail to meet patient needs, particularly among vulnerable groups and in resource-constrained settings.

• Underserved patient populations face persistent barriers to appropriate care, with minority and vulnerable groups experiencing systematic underdiagnosis and undertreatment of migraine disease, while patients in low- and middle-income countries lack access to effective therapies and experience unnecessary hospitalizations

• Regional healthcare disparities are particularly pronounced in the Middle East, where migraines are often underestimated, underreported, and undertreated due to delayed referral processes, frequent misdiagnosis, poor treatment adherence, limited accessibility to treatments, and insufficient awareness among both healthcare providers and patients

• Primary care integration challenges continue to drive suboptimal outcomes, as underdiagnosis, lack of provider training, and limited access to effective therapies—especially in resource-constrained settings—result in unnecessary hospitalizations and missed opportunities for early intervention

• Complex patient subgroups require specialized approaches, particularly patients with migraine and autoimmune disorders who show significantly lower treatment response rates (53% achieving ≥50% response versus 69% in patients without autoimmune diseases) and need tailored strategies with vigilant monitoring

• Treatment access limitations persist globally, exemplified by data from the UAE showing only 1.0% of migraine patients were prescribed newer CGRP antagonists despite their proven efficacy, while expert consensus in Saudi Arabia emphasizes the critical need for earlier initiation of effective treatments to reduce disease burden

• Diagnostic delays and accuracy issues remain problematic across age groups, with diagnostic delays averaging 3.1 years in children and 4.0 years in adults for conditions like abdominal migraine, while difficulties in symptom description and cognitive biases frequently result in repeated consultations and diminished quality of life

Targeting PACAP: A New Frontier in Migraine Prevention

Recent migraine research has identified several promising ion channel targets that may offer new therapeutic opportunities. ATP-sensitive potassium channels (K), large conductance calcium- and voltage-activated potassium channels (BK), and transient receptor potential melastatin (TRPM) channels, specifically TRPM3 and TRPM8, are being investigated for their roles in migraine pathophysiology. These ion channels represent mechanistically distinct approaches from current therapeutic options and are progressing through various stages of preclinical validation studies, clinical experimental data collection, and clinical trial evaluation.

Neuroendocrine pathways involving peptides secreted by hypothalamic nuclei have emerged as another frontier for therapeutic intervention. Oxytocin, orexins, and prolactin systems are drawing attention as potential targets for modulation with therapeutics, reflecting the growing understanding of the hypothalamic contribution to migraine pathogenesis. The exploration of these endogenous peptide systems represents a shift toward targeting central regulatory mechanisms rather than peripheral pain pathways alone.

Extracellular vesicles (EVs) represent a particularly innovative area of investigation, being explored both as biomarkers and therapeutic carriers for migraine. Their appeal stems from their role in intercellular communication, the stability of their contents, their reflection of pathological states, and their ability to carry specific bioactive molecules. Current research has identified alterations in miRNA and protein profiles in EVs from migraine patients, though these findings face reproducibility issues and numerous challenges during clinical translation. While EVs provide a promising new perspective for migraine research, this approach remains relatively immature. The drive to explore these novel targets is largely motivated by the persistent lack of therapeutic response in many patients, despite recent advances in available pharmacological options.

Beyond CGRP: The Expanding Migraine Prevention Arsenal

The migraine treatment landscape has undergone a revolutionary transformation over the past five years with the introduction of CGRP-targeted therapies, fundamentally shifting the therapeutic paradigm beyond traditional approaches. The approval of multiple novel drug classes has provided clinicians with unprecedented options for both acute and preventive migraine management. Small-molecule CGRP receptor antagonists (gepants) including ubrogepant, rimegepant, atogepant, and zavegepant, alongside the 5-HT1F receptor agonist lasmiditan, have emerged as first-in-class treatments offering migraine-specific therapy without the cardiovascular risks associated with triptans. Anti-CGRP monoclonal antibodies—erenumab, fremanezumab, galcanezumab, and eptinezumab—have established new standards for preventive treatment, with rimegepant notably becoming the first therapy approved for both acute and preventive indications.

Clinical trial data demonstrates remarkable efficacy across these novel therapeutic classes, with sustained benefits extending beyond traditional measures. Eptinezumab trials showed mean MIDAS headache days decreasing from 47.4 at baseline to 16.3 at week 104, while galcanezumab demonstrated superior efficacy in menstrually related migraine with mean reductions of -5.1 days versus -3.2 days for placebo. Atogepant's long-term data revealed progressive improvement over 52 weeks, with 84.2% of patients achieving ≥50% reduction in monthly migraine days and 48.4% experiencing complete migraine freedom. The gepants have shown particular promise when used early in the attack, with ubrogepant treatment during mild pain resulting in pain freedom rates of 47.1-55.2% compared to 23.6-26.1% when treating moderate-severe pain.

Real-world evidence has validated the clinical trial findings while revealing important healthcare utilization impacts. Erenumab initiation resulted in $896 reduction in migraine-related medical costs and significantly lower odds of emergency room visits (OR 0.60), office visits (OR 0.58), and specialist consultations (OR 0.69). Cost-effectiveness analyses demonstrate favorable profiles, with rimegepant generating an incremental cost-utility ratio of £10,309 per QALY gained. However, persistent challenges remain, including high discontinuation rates for traditional therapies, with median triptan discontinuation at 7.7 months and 70% overall discontinuation rates, highlighting the critical need for these newer therapeutic options in addressing unmet clinical needs in migraine management.

Mentari's Market Entry: High Hopes and a Clinical Conundrum

Mentari Therapeutics' emergence as a publicly traded entity through a reverse merger with InMed Pharmaceuticals, bolstered by a substantial $290 million private placement, marks a significant moment for the biopharmaceutical landscape. With a pro forma equity value of $421 million, the company is now well-capitalized to pursue its stated mission: developing antibody drugs for migraine prevention, specifically targeting PACAP and CGRP proteins. This funding is anticipated to fuel operations through 2028, by which time Mentari expects to have crucial clinical data for its two lead programs, MT-001 and MT-002.

However, a closer look at available information reveals a potential point of strategic ambiguity. While Mentari's press release clearly outlines MT-001 as a migraine prevention candidate, existing literature describes an MT-001 as a promising SARS-CoV-2 vaccine candidate, noted for its high anti-spike IgG titers and non-waning humoral response. This apparent contradiction regarding the lead asset's therapeutic area could introduce uncertainty for investors and stakeholders, demanding clear communication from Mentari to define its pipeline and strategic focus.

Entering the migraine prevention space, particularly with CGRP and PACAP targets, places Mentari in a competitive arena with established players. Success will hinge on demonstrating superior efficacy, safety, or a differentiated profile that addresses unmet needs. The significant capital infusion provides a strong foundation for clinical development, but the inherent risks of drug development—including potential delays or unexpected trial outcomes—remain. Mentari's ability to clarify its pipeline, navigate the competitive landscape, and deliver compelling clinical data will be paramount in shaping its trajectory in the coming years.